Work

Effects of risedronate on volumetric bone mineral density and CT-derived muscle–bone associations after sleeve gastrectomy: a pilot randomized controlled trial

Year: 2026
Type: article
Study design: Clinical Trial
Abstract: Sleeve gastrectomy (SG) is an effective surgical treatment for severe obesity but is associated with bone mineral density (BMD) loss. This analysis investigates postoperative bisphosphonate effects on computed tomography (CT)-derived compartmental volumetric BMD (vBMD) and associations with CT-derived muscle outcomes. The 6-month pilot study randomized 24 SG patients to once-monthly 150 mg risedronate (n = 11) or placebo (n = 13). CT scans were collected at baseline, and 6- and 12-months postoperatively to assess hip and spine vBMD. Treatment effects were estimated using a mixed linear model adjusted for sex and baseline measures, and Pearson correlations with CT-derived muscle outcomes were assessed. There were no significant vBMD differences between risedronate vs. placebo groups after SG, but 6-month trends suggest vBMD losses [mg/cm 3 ] with risedronate were potentially attenuated in the trabecular compartment of the total hip [− 8.8 vs. − 9.6], femoral neck [− 3.6 vs. − 7.3], and L1–L4 vertebrae [− 8.4 vs. − 11.1]. Muscle–bone correlations were not significant but trends suggest larger and less fat infiltrated trunk muscles may protect against spine vBMD loss. This pilot study did not find a significant treatment effect of risedronate on vBMD in SG patients, but exploratory findings in relation with muscle measures warrant additional investigation in a larger study.
Language: English
Field: Medicine
Open Access status: gold
Estimated APC paid: $2,690
OpenAlex ID: W7236157142
FWCI:
Cites: 52
Cited by:
Related to: 10